Analysed ANIXA BIOSCIENCES INC (ANIX:NASDAQ) News Sources
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
01-06-2026
yahoo.com
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
11-06-2026
yahoo.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
26-06-2026
yahoo.com
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
29-06-2026
yahoo.com
Anixa Biosciences secures Korean patent for breast cancer vaccine
30-06-2026
pharmaceutical-technology.com
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
06-07-2026
yahoo.com
What is the current price of ANIXA BIOSCIENCES INC (ANIX:NASDAQ)?
The current price of ANIXA BIOSCIENCES INC (ANIX:NASDAQ) is $3.49.
ANIXA BIOSCIENCES INC (ANIX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ANIXA BIOSCIENCES INC (ANIX:NASDAQ) since the previous trading day is $0.01.
ANIXA BIOSCIENCES INC (ANIX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ANIXA BIOSCIENCES INC (ANIX:NASDAQ) since the previous trading day is 0.2874%.
What is the most recent average sentiment score for ANIXA BIOSCIENCES INC (ANIX:NASDAQ)?
The most recent average sentiment score for ANIXA BIOSCIENCES INC (ANIX:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ANIXA BIOSCIENCES INC (ANIX:NASDAQ)?
The most recent sentiment for ANIXA BIOSCIENCES INC (ANIX:NASDAQ) is .
SEC-8K** Filing Available For ANIXA BIOSCIENCES INC (ANIX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.